Share Repurchase Plan Approved by Becton, Dickinson and Company (NYSE:BDX) Board

Becton, Dickinson and Company (NYSE:BDX) announced that its Board of Directors has authorized a stock buyback plan on Tuesday, January 27th, RTT News reports. The company plans to repurchase $10.00 million in outstanding shares. This repurchase authorization permits the medical instruments supplier to buy up to 0% of its shares through open market purchases. Shares repurchase plans are typically an indication that the company’s management believes its stock is undervalued.

Analyst Upgrades and Downgrades

Several equities analysts recently commented on BDX shares. Wall Street Zen downgraded shares of Becton, Dickinson and Company from a “buy” rating to a “hold” rating in a report on Saturday, November 8th. Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Becton, Dickinson and Company in a research report on Wednesday, October 8th. Stifel Nicolaus raised their price objective on Becton, Dickinson and Company from $210.00 to $215.00 and gave the company a “buy” rating in a research report on Wednesday, January 7th. Royal Bank Of Canada raised their price target on shares of Becton, Dickinson and Company from $202.00 to $210.00 and gave the company a “sector perform” rating in a report on Wednesday, December 17th. Finally, Piper Sandler reduced their price objective on shares of Becton, Dickinson and Company from $200.00 to $190.00 and set a “neutral” rating for the company in a research note on Friday, November 7th. Four investment analysts have rated the stock with a Buy rating and nine have issued a Hold rating to the company. According to data from MarketBeat.com, Becton, Dickinson and Company currently has a consensus rating of “Hold” and an average price target of $207.64.

Becton, Dickinson and Company Stock Down 0.0%

BDX stock opened at $203.41 on Wednesday. The firm has a market cap of $57.95 billion, a PE ratio of 34.89, a PEG ratio of 2.25 and a beta of 0.23. The company has a debt-to-equity ratio of 0.69, a quick ratio of 0.64 and a current ratio of 1.11. Becton, Dickinson and Company has a one year low of $162.29 and a one year high of $251.99. The firm’s 50 day moving average price is $197.87 and its 200-day moving average price is $190.90.

Becton, Dickinson and Company (NYSE:BDX) last posted its earnings results on Thursday, November 6th. The medical instruments supplier reported $3.96 EPS for the quarter, beating analysts’ consensus estimates of $3.92 by $0.04. Becton, Dickinson and Company had a net margin of 7.68% and a return on equity of 16.42%. The company had revenue of $5.89 billion for the quarter, compared to analysts’ expectations of $5.91 billion. During the same quarter in the prior year, the company posted $3.81 earnings per share. Becton, Dickinson and Company’s revenue for the quarter was up 8.3% compared to the same quarter last year. Becton, Dickinson and Company has set its FY 2026 guidance at 14.750-15.050 EPS. On average, equities research analysts anticipate that Becton, Dickinson and Company will post 14.43 EPS for the current year.

Becton, Dickinson and Company Increases Dividend

The company also recently announced a quarterly dividend, which was paid on Wednesday, December 31st. Shareholders of record on Monday, December 8th were given a $1.05 dividend. The ex-dividend date of this dividend was Monday, December 8th. This is a positive change from Becton, Dickinson and Company’s previous quarterly dividend of $1.04. This represents a $4.20 dividend on an annualized basis and a yield of 2.1%. Becton, Dickinson and Company’s dividend payout ratio is presently 72.04%.

Key Headlines Impacting Becton, Dickinson and Company

Here are the key news stories impacting Becton, Dickinson and Company this week:

• Positive Sentiment: Board declared a quarterly dividend of $1.05 per share (payable March 31; record date March 10), a direct shareholder return that supports income-focused investors. BD Board Declares Dividend, Authorizes 10 Million Additional Share Repurchases
• Positive Sentiment: Company authorized an additional $10 million of share repurchases and has completed ~$250 million of repurchases in FY26 to date — buybacks and the dividend together signal management is focused on returning capital. BD Board Declares Dividend, Authorizes 10 Million Additional Share Repurchases
• Positive Sentiment: Spin-off progress: BD set the Feb. 5 record date for the spin-off of its Biosciences & Diagnostic Solutions business and Waters shareholders approved the combination — a transaction that could unlock discrete value for BD shareholders and refocus BD on core med-tech operations. BD Announces Record Date for the Spin-Off Waters Shareholders Approve Combination
• Positive Sentiment: Product/technology: BD launched BD Research Cloud 7.0 with an AI-powered Horizon Panel Maker for advanced flow cytometry — a growth/competitive positive that supports longer-term revenue potential in life-science tools. BDX Introduces BD Research Cloud 7.0
• Neutral Sentiment: Upcoming results: BD scheduled its Q1 FY2026 earnings webcast — a near-term catalyst that could produce volatility depending on results and guidance. BD to Announce Financial Results for its First Quarter of Fiscal 2026
• Neutral Sentiment: Positive analyst/media pieces (Zacks, MSN) highlight BDX as an attractive value/momentum name — helpful for sentiment but not an immediate fundamental change. Why Becton Dickinson (BDX) is a top value stock for the long term Why Becton Dickinson (BDX) is a Top Value Stock
• Negative Sentiment: Scale concern: the newly authorized $10 million repurchase is small relative to BD’s ~$58B market cap, so some investors may view the buyback as immaterial to shares outstanding; expectations for larger capital returns may not be met. RTT News Buybacks

Insider Buying and Selling at Becton, Dickinson and Company

In other news, EVP Michael David Garrison sold 1,610 shares of Becton, Dickinson and Company stock in a transaction on Thursday, January 15th. The stock was sold at an average price of $207.46, for a total value of $334,010.60. Following the completion of the sale, the executive vice president directly owned 12,095 shares of the company’s stock, valued at approximately $2,509,228.70. The trade was a 11.75% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, Director Bertram L. Scott sold 217 shares of the stock in a transaction dated Friday, November 7th. The stock was sold at an average price of $176.58, for a total value of $38,317.86. Following the transaction, the director directly owned 35,816 shares in the company, valued at approximately $6,324,389.28. The trade was a 0.60% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last 90 days, insiders have sold 2,605 shares of company stock valued at $524,643. Company insiders own 0.40% of the company’s stock.

About Becton, Dickinson and Company

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.